Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 14;13:1016377. doi: 10.3389/fneur.2022.1016377

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Hatchwell, Smith, Jalilzadeh, Bruno, Taoufik, Hendel-Chavez, Liblau, Brassat, Martin-Blondel, Wiendl, Schwab, Cortese, Monaco, Imberti, Capra, Oksenberg, Gasnault, Stankoff, Richmond, Rancour, Koralnik, Hanson, Major, Chow and Eis.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Predictive risk comparison to HLA-B*1502, positive predictive value (PPV) vs. number needed to treat (NNT). Results for a 4-variant PML risk test are shown in comparison to the HLA-B*15:02 test that is required in Asian populations before administering carbamazepine (CBZ). CBZ is a cause of the serious adverse event Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The proposed 4-variant PML risk test data point (●) is based on the total drug-exposed PML cases (Table 5) and a PML incidence rate of 3% (17). The HLA-B*15:02 SJS/TEN risk test data point (Δ) is based on results reported in Shi et al. (54). More Utility is defined as higher PPV and lower NNT and Less Utility is defined as lower PPV and higher NNT.